Dianthus Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. Our primary clinical-stage candidate is claseprubart, a monoclonal antibody engineered for an extended half-life, improved potency, and high selectivity for the active C1s complement protein. This design aims to allow for less frequent, convenient self-administered subcutaneous injections using a pre-filled pen. By selectively inhibiting the classical complement pathway, claseprubart may also reduce the risk of infection from encapsulated bacteria by preserving the immune activity of the lectin and alternative pathways. We believe claseprubart could address various complement-dependent diseases, offering potential improvements over existing and developing therapies in terms of efficacy, safety, or dosing convenience. Our second clinical-stage candidate, DNTH212, is a bifunctional fusion protein. It targets plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production and simultaneously inhibits BAFF/APRIL to suppress B cell function. This approach targets both the innate and adaptive immune systems through two clinically validated pathways known to drive autoimmune disease, potentially addressing multiple autoimmune indications with improved outcomes. DNTH212 is also designed for convenient, infrequent, self-administered subcutaneous injections suitable for a pre-filled pen. Claseprubart, our most advanced product candidate, is a clinical-stage, highly potent, highly selective, and fully human monoclonal immunoglobulin G4 with picomolar binding affinity. It is designed to selectively bind only to the active form of C1s, which is generated during complement activation. C1s inhibition is a validated complement target in autoimmune and inflammatory fields, preventing the progression of the classical pathway cascade. Claseprubart incorporates YTE half-life extension technology, involving a specific three amino acid change in the Fc domain, and has a pharmacokinetic profile intended to support less frequent, lower dose, self-administration as a convenient subcutaneous injection.